XML 43 R30.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Supplemental data | 9 Months Ended
--- | ---
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Supplemental data | Supplemental data The following information is presented as supplemental data as required by the indentures governing the Company’s senior notes. Condensed Consolidating Statements of Income
|  | Consolidated Total |  | Physician Groups |  | Unrestricted Subsidiaries |  | Company and Restricted Subsidiaries(1)
For the nine months ended September 30, 2018 |  |  |  |
Patient service operating revenues |  | $ | 7,980,178 |  |  | $ | — |  |  | $ | — |  |  | $ | 7,980,178 |
Provision for uncollectible accounts |  | (35,838 | ) |  | — |  |  | — |  |  | (35,838 | )
Net patient service operating revenues |  | 7,944,340 |  |  | — |  |  | — |  |  | 7,944,340 |
Other revenues |  | 639,387 |  |  | — |  |  | — |  |  | 639,387 |
Total net operating revenues |  | 8,583,727 |  |  | — |  |  | — |  |  | 8,583,727 |
Operating expenses |  | 7,445,811 |  |  | — |  |  | — |  |  | 7,445,811 |
Operating income |  | 1,137,916 |  |  | — |  |  | — |  |  | 1,137,916 |
Debt expense, including refinancing charges |  | (359,135 | ) |  | — |  |  | — |  |  | (359,135 | )
Other income |  | 10,583 |  |  | — |  |  | — |  |  | 10,583 |
Income tax expense |  | 206,652 |  |  | — |  |  | — |  |  | 206,652 |
Net income from continuing operations |  | 582,712 |  |  | — |  |  | — |  |  | 582,712 |
Net (loss) income from discontinued operations, net of tax |  | (147,829 | ) |  | 20,773 |  |  | 298 |  |  | (168,900 | )
Net income |  | 434,883 |  |  | 20,773 |  |  | 298 |  |  | 413,812 |
Less: Net income attributable to noncontrolling interests |  | (125,717 | ) |  | (6,961 | ) |  | — |  |  | (118,756 | )
Net income attributable to DaVita Inc. |  | $ | 309,166 |  |  | $ | 13,812 |  |  | $ | 298 |  |  | $ | 295,056 |
(1) | After elimination of the unrestricted subsidiaries and the physician groups.
Condensed Consolidating Statements of Comprehensive Income
|  | Consolidated Total |  | Physician Groups |  | Unrestricted Subsidiaries |  | Company and Restricted Subsidiaries(1)
For the nine months ended September 30, 2018 |  |  |  |
Net income |  | $ | 434,883 |  |  | $ | 20,773 |  |  | $ | 298 |  |  | $ | 413,812 |
Other comprehensive loss |  | (33,976 | ) |  | — |  |  | — |  |  | (33,976 | )
Total comprehensive income |  | 400,907 |  |  | 20,773 |  |  | 298 |  |  | 379,836 |
Less: Comprehensive income attributable to the noncontrolling interests |  | (125,717 | ) |  | (6,961 | ) |  | — |  |  | (118,756 | )
Comprehensive income attributable to DaVita Inc. |  | $ | 275,190 |  |  | $ | 13,812 |  |  | $ | 298 |  |  | $ | 261,080 |
(1) | After elimination of the unrestricted subsidiaries and the physician groups.
Condensed Consolidating Balance Sheets
|  | Consolidated Total |  | Physician Groups |  | Unrestricted Subsidiaries |  | Company and Restricted Subsidiaries(1)
As of September 30, 2018 |  |  |  |
Cash and cash equivalents |  | $ | 448,215 |  |  | $ | — |  |  | $ | — |  |  | $ | 448,215 |
Restricted cash and equivalents |  | 91,940 |  |  | — |  |  | — |  |  | 91,940 |
Accounts receivable, net |  | 1,847,086 |  |  | — |  |  | — |  |  | 1,847,086 |
Other current assets |  | 594,474 |  |  | — |  |  | — |  |  | 594,474 |
Current assets held for sale, net |  | 5,947,786 |  |  | 567,216 |  |  | 3,031 |  |  | 5,377,539 |
Total current assets |  | 8,929,501 |  |  | 567,216 |  |  | 3,031 |  |  | 8,359,254 |
Property and equipment, net |  | 3,275,636 |  |  | — |  |  | — |  |  | 3,275,636 |
Amortizable intangibles, net |  | 97,609 |  |  | — |  |  | — |  |  | 97,609 |
Other long-term assets |  | 352,384 |  |  | — |  |  | — |  |  | 352,384 |
Goodwill |  | 6,702,659 |  |  | — |  |  | — |  |  | 6,702,659 |
Total assets |  | $ | 19,357,789 |  |  | $ | 567,216 |  |  | $ | 3,031 |  |  | $ | 18,787,542 |
Current liabilities |  | $ | 3,435,483 |  |  | $ | — |  |  | $ | — |  |  | $ | 3,435,483 |
Current liabilities held for sale |  | 1,419,621 |  |  | 350,640 |  |  | — |  |  | 1,068,981 |
Payables to parent |  | — |  |  | 78,496 |  |  | 3,031 |  |  | (81,527 | )
Long-term debt and other long-term liabilities |  | 9,409,011 |  |  | — |  |  | — |  |  | 9,409,011 |
Noncontrolling interests subject to put provisions |  | 1,064,412 |  |  | — |  |  | — |  |  | 1,064,412 |
Total DaVita Inc. shareholders’ equity |  | 3,824,649 |  |  | 138,080 |  |  | — |  |  | 3,686,569 |
Noncontrolling interests not subject to put provisions |  | 204,613 |  |  | — |  |  | — |  |  | 204,613 |
Shareholders’ equity |  | 4,029,262 |  |  | 138,080 |  |  | — |  |  | 3,891,182 |
Total liabilities and shareholder’s equity |  | $ | 19,357,789 |  |  | $ | 567,216 |  |  | $ | 3,031 |  |  | $ | 18,787,542 |
(1) | After elimination of the unrestricted subsidiaries and the physician groups.
Condensed Consolidating Statements of Cash Flows
|  | Consolidated Total |  | Physician Groups |  | Unrestricted Subsidiaries |  | Company and Restricted Subsidiaries(1)
For the nine months ended September 30, 2018 |  |  |  |
Cash flows from operating activities: |  |  |  |  |  |  |  |
Net income |  | $ | 434,883 |  |  | $ | 20,773 |  |  | $ | 298 |  |  | $ | 413,812 |
Changes in operating and intercompany assets and liabilities and non-cash items included in net income |  | 947,365 |  |  | 77,229 |  |  | (298 | ) |  | 870,434 |
Net cash provided by operating activities |  | 1,382,248 |  |  | 98,002 |  |  | — |  |  | 1,284,246 |
Cash flows from investing activities: |  |  |  |  |  |  |  |  |  |  |  |
Additions of property and equipment |  | (705,659 | ) |  | (2,575 | ) |  | — |  |  | (703,084 | )
Acquisitions |  | (113,526 | ) |  | — |  |  | — |  |  | (113,526 | )
Proceeds from asset and business sales |  | 135,268 |  |  | — |  |  | — |  |  | 135,268 |
Investments and other items |  | 22,598 |  |  | (1 | ) |  | — |  |  | 22,599 |
Net cash used in investing activities |  | (661,319 | ) |  | (2,576 | ) |  | — |  |  | (658,743 | )
Cash flows from financing activities: |  |  |  |  |  |  |  |  |  |  |  |
Long-term debt |  | 845,836 |  |  | — |  |  | — |  |  | 845,836 |
Intercompany |  | — |  |  | 77,286 |  |  | — |  |  | (77,286 | )
Other items |  | (1,269,175 | ) |  | — |  |  | — |  |  | (1,269,175 | )
Net cash (used in) provided by financing activities |  | (423,339 | ) |  | 77,286 |  |  | — |  |  | (500,625 | )
Effect of exchange rate changes on cash, cash equivalents and restricted cash |  | (5,790 | ) |  | — |  |  | — |  |  | (5,790 | )
Net increase in cash, cash equivalents and restricted cash |  | 291,800 |  |  | 172,712 |  |  | — |  |  | 119,088 |
Less: Net increase in cash, cash equivalents and restricted cash from discontinued operations |  | 270,565 |  |  | 172,712 |  |  | — |  |  | 97,853 |
Net increase in cash, cash equivalents and restricted cash from continuing operations |  | 21,235 |  |  | — |  |  | — |  |  | 21,235 |
Cash, cash equivalents and restricted cash of continuing operations at beginning of the year |  | 518,920 |  |  | — |  |  | — |  |  | 518,920 |
Cash, cash equivalents and restricted cash of continuing operations at end of the period |  | $ | 540,155 |  |  | $ | — |  |  | $ | — |  |  | $ | 540,155 |
(1) | After elimination of the unrestricted subsidiaries and the physician groups.

X
- Definition The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement. + References No definition available. + Details
Name: | us-gaap_AdditionalFinancialInformationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration